SIGLEC1 and multiple sclerosis: Interestingly, CD169 (or Siglec1) was proposed as an indicator of the activity in an inflammatory CNS, due to the results showing that CD169-expressing myeloid cells were abundantly located in an active inflammatory site of the CNS, including in active multiple sclerosis lesions, acute infectious and malignant diseases.